The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
about
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary diseaseStepping down asthma treatment: how and whenLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthmaStopping long-acting beta 2 -agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroidsLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta 2 -agonists (LABA) for adults with asthmaAddition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in childrenStopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroidsStopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroidsStopping long-acting beta2-agonists (LABA) for adults with asthma well-controlled on LABA and inhaled corticosteroidsAddition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthmaBeta₂-agonists for exercise-induced asthmaAnti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenSafety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviewsRegular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with formoterol for chronic asthma: serious adverse eventsSafety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviewsRegular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsRegular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse eventsSafety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviewsOverview of the safety of regular formoterol or salmeterol in children with asthmaAsthma challenges: The place of inhaled long-acting beta-agonistsAddition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in childrenRegular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsRegular fixed-dose treatment with formoterol and inhaled corticosteroids versus regular treatment with salmeterol and inhaled corticosteroids for chronic asthma: serious adverse eventsBeta-2 agonists for exercise induced asthmaRegular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse eventsRegular treatment with formoterol for chronic asthma: serious adverse eventsRegular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with salmeterol for chronic asthma: serious adverse eventsLong-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidBeta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine modelAsthmaPatient perspectives on fluticasone-vilanterol versus other corticosteroid combination products for the treatment of asthmaPharmacotherapy in the management of asthma in the elderly: a review of clinical studiesNew combination treatments in the management of asthma: focus on fluticasone/vilanterolLong-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studiesThe Danish National Database for Asthma: establishing clinical quality indicatorsSpotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapyA novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulation
P2860
Q22305858-E0D60670-61E9-40F3-AA88-D59A0569F35AQ23916999-CAE7D2C2-1FAE-4620-BF3B-869DDA8A454AQ24187031-B65D2603-7F99-4E01-8851-BE8166F8B4FFQ24187082-A3D604E9-859B-4C22-B228-D02F132E4E35Q24187322-4C59EA96-A749-40BC-A2AA-D2386CF0D759Q24187686-FC3828E0-5EA6-4F28-B33F-CF023054DFA1Q24187884-49084FF9-57C3-47DE-9B79-703A1741ADEAQ24193977-60B50FA6-127E-49CF-BABE-A2A44CEDA05AQ24194037-234D2289-3054-4E46-B669-6A56D41DEA43Q24197585-41AF0D52-38E4-4A44-84FF-A864028E3C26Q24197597-C2284753-806B-4C57-B523-D68DC9E4E3A4Q24197682-61FB1B32-C187-4B4F-BC54-B7617162C29BQ24198890-71FB4DD2-C65B-4C66-B0A6-208C6602B387Q24199079-1CFBAAB6-4F18-46A9-91C3-50CC330774D3Q24200353-8E893FEC-F953-4366-83B4-4C997DA15563Q24200620-C6FA9892-E467-4E86-81C0-4017D6B2CA1DQ24201048-C5F63370-F51B-4E0A-90AF-2A244D73B943Q24202005-9BAF44AF-9651-4648-A8D3-F98BCD217DBCQ24202052-D701FF62-0228-4DA3-8A89-2381F2C90733Q24202543-C02BA76C-3FFD-4437-9500-B503B4AFA695Q24235697-93C61552-CBD3-45AB-BB9F-7E644F3A0A7EQ24239922-1AA587CD-E7E3-49C7-A4D7-3DBAA1521384Q24240282-8A761DE8-62FC-4C6E-83F9-67175E2A94FBQ24240671-6261D816-E607-423D-9DE2-CC0FEFFD32A7Q24240704-4F3B055E-2CA9-4316-9D5C-C1FCDDC60831Q24240832-04BADCB3-8A37-49E6-A38A-29003B53BBFFQ24241250-2C31A759-08BA-4397-9808-C04C88CCDB23Q24241453-FEA820C1-9869-4E5E-BAC8-EE9797D50E1AQ24241740-E89B18A4-3A57-456F-806A-9D97E91AAAC1Q24241960-26403353-7BAD-4481-B355-D06B18CED86AQ24246441-637948F6-396D-4626-AA3E-B3AAB65179CAQ24646260-B9456C46-BBD3-4902-A932-BD144F7B0316Q24682388-BAA84BC0-26AA-4DDD-AF59-2D7078C5ACC3Q26743444-30F19DC0-0AE5-4277-8684-DADBDA7A8566Q26769046-723F90D1-8BA6-4B45-87DF-435C5A627A06Q26852898-5A3A35A3-E5DE-4282-A884-62DC79C4A132Q27027449-157638E4-F492-4337-ACEF-067320FE56E5Q28074257-3F304E3C-8EFD-4DBD-B1FC-06544E7D0DCCQ28074802-E0942C01-CED1-4E60-BDF9-F71D410CBFDAQ28258154-6D6FCBF7-08E9-4422-96FA-678F2221CDA3
P2860
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
The Salmeterol Multicenter Ast ...... armacotherapy plus salmeterol.
@en
The Salmeterol Multicenter Ast ...... armacotherapy plus salmeterol.
@nl
type
label
The Salmeterol Multicenter Ast ...... armacotherapy plus salmeterol.
@en
The Salmeterol Multicenter Ast ...... armacotherapy plus salmeterol.
@nl
prefLabel
The Salmeterol Multicenter Ast ...... armacotherapy plus salmeterol.
@en
The Salmeterol Multicenter Ast ...... armacotherapy plus salmeterol.
@nl
P2093
P356
P1433
P1476
The Salmeterol Multicenter Ast ...... armacotherapy plus salmeterol.
@en
P2093
Harold S Nelson
Paul M Dorinsky
SMART Study Group
Scott T Weiss
Steven W Yancey
P356
10.1378/CHEST.129.1.15
P407
P577
2006-01-01T00:00:00Z